Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

MicroRNAs in Colon and Rectal Cancer - Novel Biomarkers from Diagnosis to Therapy

Author(s): Ying Yang, Wen-Jian Meng* and Zi-Qiang Wang

Volume 20, Issue 8, 2020

Page: [1211 - 1226] Pages: 16

DOI: 10.2174/1871530320666200506075219

Price: $65

Abstract

Colorectal cancer (CRC) is one of the most common cancers and a significant cause of tumor- related deaths worldwide. Traditional biomarkers, such as CEA and CA199, are not sensitive enough to provide useful information for early diagnosis and treatment and are rather used to track the clinical progression of the disease. There is growing evidence that microRNAs (miRNA) are potentially superior to traditional biomarkers as promising non-invasive biomarkers for the timely diagnosis and prediction of prognosis or treatment response in the management of CRC. In this review, the latest studies on the dysregulation of miRNAs expression in CRC and the potential for miRNAs to serve as biomarkers were collected. Given the limitations of miRNA, as discussed in this paper, its clinical applications as a diagnostic biomarker should be limited to use in combination with other biomarkers. Further research is necessary to elucidate the clinical applications of miRNA in therapy for CRC.

Keywords: Colorectal cancer, microRNAs, diagnosis, prognosis, radiotherapy, chemoradiotherapy

« Previous Next »
Graphical Abstract

[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[2]
El-Shami, K.; Oeffinger, K.C.; Erb, N.L.; Willis, A.; Bretsch, J.K.; Pratt-Chapman, M.L.; Cannady, R.S.; Wong, S.L.; Rose, J.; Barbour, A.L.; Stein, K.D.; Sharpe, K.B.; Brooks, D.D.; Cowens-Alvarado, R.L. American cancer society colorectal cancer survivorship care guidelines. CA Cancer J. Clin., 2015, 65(6), 428-455. [J].
[http://dx.doi.org/10.3322/caac.21286] [PMID: 26348643]
[3]
Locker, G.Y.; Hamilton, S.; Harris, J.; Jessup, J.M.; Kemeny, N.; Macdonald, J.S.; Somerfield, M.R.; Hayes, D.F.; Bast, R.C. Jr ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol., 2006, 24(33), 5313-5327.
[http://dx.doi.org/10.1200/JCO.2006.08.2644] [PMID: 17060676]
[4]
Morikawa, T.; Kato, J.; Yamaji, Y.; Wada, R.; Mitsushima, T.; Shiratori, Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology, 2005, 129(2), 422-428.
[http://dx.doi.org/10.1016/j.gastro.2005.05.056] [PMID: 16083699]
[5]
Yan, S.; Liu, Z.; Yu, S.; Bao, Y. Diagnostic value of methylated septin9 for colorectal cancer screening: A meta-analysis. Med. Sci. Monit., 2016, 22, 3409-3418.
[http://dx.doi.org/10.12659/MSM.900590] [PMID: 27665580]
[6]
Niedermaier, T.; Weigl, K.; Hoffmeister, M.; Brenner, H. Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: meta-analysis and modeling. Eur. J. Epidemiol., 2017, 32(6), 481-493.
[http://dx.doi.org/10.1007/s10654-017-0279-2] [PMID: 28667446]
[7]
Cooper, G.S.; Kou, T.D.; Rex, D.K. Complications following colonoscopy with anesthesia assistance: A population-based analysis. JAMA Intern. Med., 2013, 173(7), 551-556.
[http://dx.doi.org/10.1001/jamainternmed.2013.2908] [PMID: 23478904]
[8]
Hammond, W.A.; Swaika, A.; Mody, K. Pharmacologic resistance in colorectal cancer: a review. Ther. Adv. Med. Oncol., 2016, 8(1), 57-84.
[http://dx.doi.org/10.1177/1758834015614530] [PMID: 26753006]
[9]
Young, P.E.; Womeldorph, C.M.; Johnson, E.K.; Maykel, J.A.; Brucher, B.; Stojadinovic, A.; Avital, I.; Nissan, A.; Steele, S.R. Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J. Cancer, 2014, 5(4), 262-271.
[http://dx.doi.org/10.7150/jca.7988] [PMID: 24790654]
[10]
Van Cutsem, E.; Cervantes, A.; Nordlinger, B.; Arnold, D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2014, 25(Suppl. 3), iii1-iii9.
[http://dx.doi.org/10.1093/annonc/mdu260] [PMID: 25190710]
[11]
Ji, D.; Qiao, M.; Yao, Y.; Li, M.; Chen, H.; Dong, Q.; Jia, J.; Cui, X.; Li, Z.; Xia, J.; Gu, J. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients. EBioMedicine, 2018, 35, 189-197.
[http://dx.doi.org/10.1016/j.ebiom.2018.08.042] [PMID: 30166271]
[12]
Zen, K.; Zhang, C.Y. Circulating microRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev., 2012, 32(2), 326-348.
[http://dx.doi.org/10.1002/med.20215] [PMID: 22383180]
[13]
Lin, S.; Gregory, R.I.; Gregory, R.I. MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer, 2015, 15(6), 321-333.
[http://dx.doi.org/10.1038/nrc3932] [PMID: 25998712]
[14]
Aslam, M.I.; Taylor, K.; Pringle, J.H.; Jameson, J.S. MicroRNAs are novel biomarkers of colorectal cancer. Br. J. Surg., 2009, 96(7), 702-710.
[http://dx.doi.org/10.1002/bjs.6628] [PMID: 19526617]
[15]
Detassis, S.; Grasso, M.; Del Vescovo, V.; Denti, M.A. microRNAs Make the Call in Cancer Personalized Medicine. Front. Cell Dev. Biol., 2017, 5, 86.
[http://dx.doi.org/10.3389/fcell.2017.00086] [PMID: 29018797]
[16]
Mokutani, Y.; Uemura, M.; Munakata, K.; Okuzaki, D.; Haraguchi, N.; Takahashi, H.; Nishimura, J.; Hata, T.; Murata, K.; Takemasa, I.; Mizushima, T.; Doki, Y.; Mori, M.; Yamamoto, H. Down regulation of microRNA-132 is associated with poor prognosis of colorectal cancer. Ann. Surg. Oncol., 2016, 23(Suppl. 5), 599-608.
[http://dx.doi.org/10.1245/s10434-016-5133-3] [PMID: 26868958]
[17]
Drusco, A.; Nuovo, G.J.; Zanesi, N.; Di Leva, G.; Pichiorri, F.; Volinia, S.; Fernandez, C.; Antenucci, A.; Costinean, S.; Bottoni, A.; Rosito, I.A.; Liu, C.G.; Burch, A.; Acunzo, M.; Pekarsky, Y.; Alder, H.; Ciardi, A.; Croce, C.M. MicroRNA profiles discriminate among colon cancer metastasis. PLoS One, 2014, 9(6), e96670.
[http://dx.doi.org/10.1371/journal.pone.0096670] [PMID: 24921248]
[18]
Ferracin, M.; Lupini, L.; Mangolini, A.; Negrini, M. Circulating Non-coding RNA as Biomarkers in Colorectal Cancer. Non-coding RNAs in Colorectal Cancer; Slaby, O. Calin G. Eds.; Advances in Experimental Medicine and Biology; , 2016, Vol. 937, pp. 171-181.
[http://dx.doi.org/10.1007/978-3-319-42059-2_9]
[19]
Ren, A.; Dong, Y.; Tsoi, H.; Yu, J. Detection of miRNA as noninvasive biomarkers of colorectal cancer. Int. J. Mol. Sci., 2015, 16(2), 2810-2823.
[http://dx.doi.org/10.3390/ijms16022810] [PMID: 25633103]
[20]
Schee, K.; Boye, K.; Abrahamsen, T.W.; Fodstad, Ø.; Flatmark, K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer, 2012, 12, 505.
[http://dx.doi.org/10.1186/1471-2407-12-505] [PMID: 23121918]
[21]
Kanaan, Z.; Rai, S.N.; Eichenberger, M.R.; Roberts, H.; Keskey, B.; Pan, J.; Galandiuk, S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann. Surg., 2012, 256(3), 544-551.
[http://dx.doi.org/10.1097/SLA.0b013e318265bd6f] [PMID: 22868372]
[22]
Ahmed, F.E.; Amed, N.C.; Vos, P.W.; Bonnerup, C.; Atkins, J.N.; Casey, M.; Nuovo, G.J.; Naziri, W.; Wiley, J.E.; Allison, R.R. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genom. Proteom., 2012, 9(4), 179-192.
[PMID: 22798503]
[23]
Coebergh van den Braak, R.R.J.; Sieuwerts, A.M.; Lalmahomed, Z.S.; Smid, M.; Wilting, S.M.; Bril, S.I.; Xiang, S.; van der Vlugt-Daane, M.; de Weerd, V.; van Galen, A.; Biermann, K.; van Krieken, J.H.J.M.; Kloosterman, W.P.; Foekens, J.A.; Martens, J.W.M.; IJzermans, J.N.M. Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Sci. Rep., 2018, 8(1), 5242.
[http://dx.doi.org/10.1038/s41598-018-22532-1] [PMID: 29588449]
[24]
Hollis, M.; Nair, K.; Vyas, A.; Chaturvedi, L.S.; Gambhir, S.; Vyas, D. MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity. World J. Gastroenterol., 2015, 21(27), 8284-8292.
[http://dx.doi.org/10.3748/wjg.v21.i27.8284] [PMID: 26217080]
[25]
Wu, X.; Li, S.; Xu, X.; Wu, S.; Chen, R.; Jiang, Q.; Li, Y.; Xu, Y. The potential value of miR-1and miR-374b as biomarkers for colorectal cancer. Int. J. Clin. Exp. Pathol., 2014, 3, 2840-2851.
[26]
Chai, J.; Dong, W.; Xie, C.; Wang, L.; Han, D.L.; Wang, S.; Guo, H.L.; Zhang, Z.L. MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD. IUBMB Life, 2015, 67(3), 191-201.
[http://dx.doi.org/10.1002/iub.1361] [PMID: 25873402]
[27]
Wu, H.; Liang, Y.; Shen, L.; Shen, L. MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2. Biol. Open, 2016, 5(5), 563-570.
[http://dx.doi.org/10.1242/bio.015008] [PMID: 27095441]
[28]
Zhou, Y.; Wan, G.; Spizzo, R.; Ivan, C.; Mathur, R.; Hu, X.; Ye, X.; Lu, J.; Fan, F.; Xia, L.; Calin, G.A.; Ellis, L.M.; Lu, X. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol. Oncol., 2014, 8(1), 83-92.
[http://dx.doi.org/10.1016/j.molonc.2013.09.004] [PMID: 24145123]
[29]
Rasmussen, M.H.; Jensen, N.F.; Tarpgaard, L.S.; Qvortrup, C.; Rømer, M.U.; Stenvang, J.; Hansen, T.P.; Christensen, L.L.; Lindebjerg, J.; Hansen, F.; Jensen, B.V.; Hansen, T.F.; Pfeiffer, P.; Brünner, N.; Ørntoft, T.F.; Andersen, C.L. High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol. Oncol., 2013, 7(3), 637-646.
[http://dx.doi.org/10.1016/j.molonc.2013.02.016] [PMID: 23506979]
[30]
Si, H.; Sun, X.; Chen, Y.; Cao, Y.; Chen, S.; Wang, H.; Hu, C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J. Cancer Res. Clin. Oncol., 2013, 139(2), 223-229.
[http://dx.doi.org/10.1007/s00432-012-1315-y] [PMID: 23052693]
[31]
Cortez, M.A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A.K.; Calin, G.A. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol., 2011, 8(8), 467-477.
[http://dx.doi.org/10.1038/nrclinonc.2011.76] [PMID: 21647195]
[32]
Ng, E.K.; Chong, W.W.; Jin, H.; Lam, E.K.; Shin, V.Y.; Yu, J.; Poon, T.C.; Ng, S.S.; Sung, J.J. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut, 2009, 58(10), 1375-1381.
[http://dx.doi.org/10.1136/gut.2008.167817] [PMID: 19201770]
[33]
Matsumura, T.; Sugimachi, K.; Iinuma, H.; Takahashi, Y.; Kurashige, J.; Sawada, G.; Ueda, M.; Uchi, R.; Ueo, H.; Takano, Y.; Shinden, Y.; Eguchi, H.; Yamamoto, H.; Doki, Y.; Mori, M.; Ochiya, T.; Mimori, K. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br. J. Cancer, 2015, 113(2), 275-281.
[http://dx.doi.org/10.1038/bjc.2015.201] [PMID: 26057451]
[34]
Carter, J.V.; Galbraith, N.J.; Yang, D.; Burton, J.F.; Walker, S.P.; Galandiuk, S. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: A systematic review and meta-analysis. Br. J. Cancer, 2017, 116(6), 762-774.
[http://dx.doi.org/10.1038/bjc.2017.12] [PMID: 28152545]
[35]
Meng, W.J.; Yang, L.; Ma, Q.; Zhang, H.; Adell, G.; Arbman, G.; Wang, Z.Q.; Li, Y.; Zhou, Z.G.; Sun, X.F. MicroRNA expression profile reveals miR-17-92 and miR-143-145 cluster in synchronous colorectal cancer. Medicine (Baltimore), 2015, 94(32), e1297.
[http://dx.doi.org/10.1097/MD.0000000000001297] [PMID: 26266366]
[36]
Qu, A.; Yang, Y.; Zhang, X.; Wang, W.; Liu, Y.; Zheng, G.; Du, L.; Wang, C. Development of a preoperative prediction nomogram for lymph node metastasis in colorectal cancer based on a novel serum miRNA signature and CT scans. EBioMedicine, 2018, 37, 125-133.
[http://dx.doi.org/10.1016/j.ebiom.2018.09.052] [PMID: 30314890]
[37]
Wang, Q.; Huang, Z.; Ni, S.; Xiao, X.; Xu, Q.; Wang, L.; Huang, D.; Tan, C.; Sheng, W.; Du, X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One, 2012, 7(9), e44398.
[http://dx.doi.org/10.1371/journal.pone.0044398] [PMID: 22970209]
[38]
Vychytilova-Faltejskova, P.; Radova, L.; Sachlova, M.; Kosarova, Z.; Slaba, K.; Fabian, P.; Grolich, T.; Prochazka, V.; Kala, Z.; Svoboda, M.; Kiss, I.; Vyzula, R.; Slaby, O. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis, 2016, 37(10), 941-950.
[http://dx.doi.org/10.1093/carcin/bgw078] [PMID: 27485599]
[39]
Pesta, M.; Kucera, R.; Topolcan, O.; Karlikova, M.; Houfkova, K.; Polivka, J.; Macanova, T.; Machova, I.; Slouka, D.; Kulda, V. Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients. Cancers (Basel), 2019, 11(6), E864.
[http://dx.doi.org/10.3390/cancers11060864] [PMID: 31234350]
[40]
Siegel, R.L.; Miller, K.D.; Fedewa, S.A.; Ahnen, D.J.; Meester, R.G.S.; Barzi, A.; Jemal, A. Colorectal cancer statistics, 2017. CA Cancer J. Clin., 2017, 67(3), 177-193.
[http://dx.doi.org/10.3322/caac.21395] [PMID: 28248415]
[41]
Tan, Y.; Lin, J.J.; Yang, X.; Gou, D.M.; Fu, L.; Li, F.R.; Yu, X.F. A panel of three plasma microRNAs for colorectal cancer diagnosis. Cancer Epidemiol., 2019, 60, 67-76.
[http://dx.doi.org/10.1016/j.canep.2019.01.015] [PMID: 30925282]
[42]
Guo, S.; Zhang, J.; Wang, B.; Zhang, B.; Wang, X.; Huang, L.; Liu, H.; Jia, B. A 5-serum miRNA panel for the early detection of colorectal cancer. OncoTargets Ther., 2018, 11, 2603-2614.
[http://dx.doi.org/10.2147/OTT.S153535] [PMID: 29780253]
[43]
A.; Pericay, C.; Moya, I.; Ferrer, A.; Dotor, E.; Pisa, A.; Casalots, À.; Serra-Aracil, X.; Oliva, JC.; Ruiz, A.; Saigí, E. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol. Rep., 2013, 30, 320-326.
[http://dx.doi.org/10.3892/or.2013.2475]
[44]
Zhang, H.; Zhu, M.; Shan, X.; Zhou, X.; Wang, T.; Zhang, J.; Tao, J.; Cheng, W.; Chen, G.; Li, J.; Liu, P.; Wang, Q.; Zhu, W. A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis. Gene, 2019, 687, 246-254.
[http://dx.doi.org/10.1016/j.gene.2018.11.055] [PMID: 30458288]
[45]
Krawczyk, P.; Powrózek, T.; Olesiński, T.; Dmitruk, A.; Dziwota, J.; Kowalski, D.; Milanowski, J. Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer. Int. J. Colorectal Dis., 2017, 32(7), 1057-1060.
[http://dx.doi.org/10.1007/s00384-017-2814-8] [PMID: 28405738]
[46]
Kanaan, Z.; Roberts, H.; Eichenberger, M.R.; Billeter, A.; Ocheretner, G.; Pan, J.; Rai, S.N.; Jorden, J.; Williford, A.; Galandiuk, S. A plasma microRNA panel for detection of colorectal adenomas: A step toward more precise screening for colorectal cancer. Ann. Surg., 2013, 258(3), 400-408.
[http://dx.doi.org/10.1097/SLA.0b013e3182a15bcc] [PMID: 24022433]
[47]
Giráldez, MD.; Lozano, JJ.; Ramírez, G.; Hijona, E.; Bujanda, L.; Castells, A.; Gironella, M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin. Gastroenterol. Hepatol., 2013, 11, 681-8, e3.,
[http://dx.doi.org/10.1016/j.cgh.2012.12.009]
[48]
Yong, F.L.; Law, C.W.; Wang, C.W. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer, 2013, 13, 280.
[http://dx.doi.org/10.1186/1471-2407-13-280] [PMID: 23758639]
[49]
Huang, Z.; Huang, D.; Ni, S.; Peng, Z.; Sheng, W.; Du, X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer, 2010, 127(1), 118-126.
[http://dx.doi.org/10.1002/ijc.25007] [PMID: 19876917]
[50]
Liu, G.H.; Zhou, Z.G.; Chen, R.; Wang, M.J.; Zhou, B.; Li, Y.; Sun, X.F. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol., 2013, 34(4), 2175-2181.
[http://dx.doi.org/10.1007/s13277-013-0753-8] [PMID: 23625654]
[51]
Yamada, A.; Horimatsu, T.; Okugawa, Y.; Nishida, N.; Honjo, H.; Ida, H.; Kou, T.; Kusaka, T.; Sasaki, Y.; Yagi, M.; Higurashi, T.; Yukawa, N.; Amanuma, Y.; Kikuchi, O.; Muto, M.; Ueno, Y.; Nakajima, A.; Chiba, T.; Boland, C.R.; Goel, A. Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clin. Cancer Res., 2015, 21(18), 4234-4242.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-2793] [PMID: 26038573]
[52]
Carter, J.V.; Roberts, H.L.; Pan, J.; Rice, J.D.; Burton, J.F.; Galbraith, N.J.; Eichenberger, M.R.; Jorden, J.; Deveaux, P.; Farmer, R.; Williford, A.; Kanaan, Z.; Rai, S.N.; Galandiuk, S. A highly predictive model for diagnosis of colorectal neoplasms using plasma MicroRNA: Improving specificity and sensitivity. Ann. Surg., 2016, 264(4), 575-584.
[http://dx.doi.org/10.1097/SLA.0000000000001873] [PMID: 27471839]
[53]
Liu, X.; Xu, X.; Pan, B.; He, B.; Chen, X.; Zeng, K.; Xu, M.; Pan, Y.; Sun, H.; Xu, T.; Hu, X.; Wang, S. Circulating miR-1290 and miR-320d as novel diagnostic biomarkers of human colorectal cancer. J. Cancer, 2019, 10(1), 43-50.
[http://dx.doi.org/10.7150/jca.26723] [PMID: 30662524]
[54]
Liu, H.N.; Liu, T.T.; Wu, H.; Chen, Y.J.; Tseng, Y.J.; Yao, C.; Weng, S.Q.; Dong, L.; Shen, X.Z. Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods. Cancer Sci., 2018, 109(4), 1185-1194.
[http://dx.doi.org/10.1111/cas.13514] [PMID: 29363233]
[55]
Fang, Z.; Tang, J.; Bai, Y.; Lin, H.; You, H.; Jin, H.; Lin, L.; You, P.; Li, J.; Dai, Z.; Liang, X.; Su, Y.; Hu, Q.; Wang, F.; Zhang, Z.Y. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J. Exp. Clin. Cancer Res., 2015, 34, 86.
[http://dx.doi.org/10.1186/s13046-015-0198-6] [PMID: 26297223]
[56]
Wang, J.; Huang, S.K.; Zhao, M.; Yang, M.; Zhong, J.L.; Gu, Y.Y.; Peng, H.; Che, Y.Q.; Huang, C.Z. Identification of a circulating microRNA signature for colorectal cancer detection. PLoS One, 2014, 9(4), e87451.
[http://dx.doi.org/10.1371/journal.pone.0087451] [PMID: 24709885]
[57]
H.; Izumiya, M.; Kurioka, D.; Honma, Y.; Yamada, Y.; Furuta, K.; Gunji, T.; Ohta, H.; Okamoto, H.; Sonoda, H.; Watanabe, M.; Nakagama, H.; Yokota, J.; Kohno, T.; Tsuchiya, N. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One, 2014, 9e92921
[58]
Wang, S.; Wang, L.; Bayaxi, N.; Li, J.; Verhaegh, W.; Janevski, A.; Varadan, V.; Ren, Y.; Merkle, D.; Meng, X.; Gao, X.; Wang, H.; Ren, J.; Kuo, W.P.; Dimitrova, N.; Wu, Y.; Zhu, H. A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut, 2013, 62(2), 280-289.
[http://dx.doi.org/10.1136/gutjnl-2011-301554] [PMID: 22535378]
[59]
McDevitt, J.; Comber, H.; Walsh, P.M. Colorectal cancer incidence and survival by sub-site and stage of diagnosis: A population-based study at the advent of national screening. Ir. J. Med. Sci., 2017, 186(1), 113-121.
[http://dx.doi.org/10.1007/s11845-016-1513-8] [PMID: 27752924]
[60]
Wang, S.; Xiang, J.; Li, Z.; Lu, S.; Hu, J.; Gao, X.; Yu, L.; Wang, L.; Wang, J.; Wu, Y.; Chen, Z.; Zhu, H. A plasma microRNA panel for early detection of colorectal cancer. Int. J. Cancer, 2015, 136(1), 152-161.
[http://dx.doi.org/10.1002/ijc.28136] [PMID: 23456911]
[61]
Zheng, G.; Du, L.; Yang, X.; Zhang, X.; Wang, L.; Yang, Y.; Li, J.; Wang, C. Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma. Br. J. Cancer, 2014, 111(10), 1985-1992.
[http://dx.doi.org/10.1038/bjc.2014.489] [PMID: 25233400]
[62]
Kocarnik, J.M.; Shiovitz, S.; Phipps, A.I. Molecular phenotypes of colorectal cancer and potential clinical applications. Gastroenterol. Rep. (Oxf.), 2015, 3(4), 269-276.
[http://dx.doi.org/10.1093/gastro/gov046] [PMID: 26337942]
[63]
Saito, G.; Sadahiro, S.; Kamata, H.; Miyakita, H.; Okada, K.; Tanaka, A.; Suzuki, T. Monitoring of serum carcinoembryonic antigen levels after curative resection of colon cancer: Cutoff values determined according to preoperative levels enhance the diagnostic accuracy for recurrence. Oncology, 2017, 92(5), 276-282.
[http://dx.doi.org/10.1159/000456075] [PMID: 28178692]
[64]
Wang, J.; Wang, X.; Yu, F.; Chen, J.; Zhao, S.; Zhang, D.; Yu, Y.; Liu, X.; Tang, H.; Peng, Z. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients. Int. J. Clin. Exp. Pathol., 2015, 8(11), 14853-14863.
[PMID: 26823815]
[65]
Yang, S.H.; Jiang, J.K.; Chang, S.C.; Juang, C.J.; Lin, J.K. Clinical significance of CA19-9 in the follow-up of colorectal cancer patients with elevated preoperative serum CA19-9. Hepatogastroenterology, 2013, 60(125), 1021-1027.
[PMID: 23321120]
[66]
Yu, C.; Wan, H.; Shan, R.; Wen, W.; Li, J.; Luo, D.; Wan, R. The prognostic value of the MiR-200 family in colorectal cancer: A meta-analysis with 1882 patients. J. Cancer, 2019, 10(17), 4009-4016.
[http://dx.doi.org/10.7150/jca.27529] [PMID: 31417645]
[67]
Sun, Y.; Liu, Y.; Cogdell, D.; Calin, G.A.; Sun, B.; Kopetz, S.; Hamilton, S.R.; Zhang, W. Examining plasma microRNA markers for colorectal cancer at different stages. Oncotarget, 2016, 7(10), 11434-11449.
[http://dx.doi.org/10.18632/oncotarget.7196] [PMID: 26863633]
[68]
Bobowicz, M.; Skrzypski, M.; Czapiewski, P.; Marczyk, M.; Maciejewska, A.; Jankowski, M.; Szulgo-Paczkowska, A.; Zegarski, W.; Pawłowski, R.; Polańska, J.; Biernat, W.; Jaśkiewicz, J.; Jassem, J. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clin. Exp. Metastasis, 2016, 33(8), 765-773.
[http://dx.doi.org/10.1007/s10585-016-9810-1] [PMID: 27485175]
[69]
Basati, G.; Razavi, A.E.; Pakzad, I.; Malayeri, F.A. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumour Biol., 2016, 37(2), 1781-1788.
[http://dx.doi.org/10.1007/s13277-015-3967-0] [PMID: 26318304]
[70]
Caritg, O.; Navarro, A.; Moreno, I.; Martínez-Rodenas, F.; Cordeiro, A.; Muñoz, C.; Ruiz-Martinez, M.; Santasusagna, S.; Castellano, J.J.; Monzó, M. Identifying high-risk stage II colon cancer patients: A three-microrna-based score as a prognostic biomarker. Clin. Colorectal Cancer, 2016, 15(4), e175-e182.
[http://dx.doi.org/10.1016/j.clcc.2016.04.008] [PMID: 27247088]
[71]
Santasusagna, S.; Moreno, I.; Navarro, A.; Martinez Rodenas, F.; Hernández, R.; Castellano, J.J.; Muñoz, C.; Monzo, M. Prognostic Impact of miR-200 family members in plasma and exosomes from tumor-draining versus peripheral veins of colon cancer patients. Oncology, 2018, 95(5), 309-318.
[http://dx.doi.org/10.1159/000490726] [PMID: 30138915]
[72]
Liu, X.; Pan, B.; Sun, L.; Chen, X.; Zeng, K.; Hu, X.; Xu, T.; Xu, M.; Wang, S. Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 2018, 27(7), 746-754.
[http://dx.doi.org/10.1158/1055-9965.EPI-18-0067] [PMID: 29739748]
[73]
Fu, F.; Jiang, W.; Zhou, L.; Chen, Z. Circulating exosomal miR-17-5p and miR-92a-3p predict pathologic stage and grade of colorectal cancer. Transl. Oncol., 2018, 11(2), 221-232.
[http://dx.doi.org/10.1016/j.tranon.2017.12.012] [PMID: 29367070]
[74]
Jacob, H.; Stanisavljevic, L.; Storli, K.E.; Hestetun, K.E.; Dahl, O.; Myklebust, M.P. A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer. Sci. Rep., 2018, 8(1), 6157.
[http://dx.doi.org/10.1038/s41598-018-24519-4] [PMID: 29670141]
[75]
Zhang, J.X.; Song, W.; Chen, Z.H.; Wei, J.H.; Liao, Y.J.; Lei, J.; Hu, M.; Chen, G.Z.; Liao, B.; Lu, J.; Zhao, H.W.; Chen, W.; He, Y.L.; Wang, H.Y.; Xie, D.; Luo, J.H. Prognostic and predictive value of a microRNA signature in stage II colon cancer: A microRNA expression analysis. Lancet Oncol., 2013, 14(13), 1295-1306.
[http://dx.doi.org/10.1016/S1470-2045(13)70491-1] [PMID: 24239208]
[76]
Gregory, P.A.; Bert, A.G.; Paterson, E.L.; Barry, S.C.; Tsykin, A.; Farshid, G.; Vadas, M.A.; Khew-Goodall, Y.; Goodall, G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 2008, 10(5), 593-601.
[http://dx.doi.org/10.1038/ncb1722] [PMID: 18376396]
[77]
Maierthaler, M.; Benner, A.; Hoffmeister, M.; Surowy, H.; Jansen, L.; Knebel, P.; Chang-Claude, J.; Brenner, H.; Burwinkel, B. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int. J. Cancer, 2017, 140(1), 176-187.
[http://dx.doi.org/10.1002/ijc.30433] [PMID: 27632639]
[78]
Yuan, Z.; Baker, K.; Redman, M.W.; Wang, L.; Adams, S.V.; Yu, M.; Dickinson, B.; Makar, K.; Ulrich, N.; Böhm, J.; Wurscher, M.; Westerhoff, M.; Medwell, S.; Moonka, R.; Sinanan, M.; Fichera, A.; Vickers, K.; Grady, W.M. Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer. Br. J. Cancer, 2017, 117(8), 1202-1210.
[http://dx.doi.org/10.1038/bjc.2017.266] [PMID: 28809863]
[79]
Jin, G.; Liu, Y.; Zhang, J.; Bian, Z.; Yao, S.; Fei, B.; Zhou, L.; Yin, Y.; Huang, Z. A panel of serum exosomal microRNAs as predictive markers for chemoresistance in advanced colorectal cancer. Cancer Chemother. Pharmacol., 2019, 84(2), 315-325.
[http://dx.doi.org/10.1007/s00280-019-03867-6] [PMID: 31089750]
[80]
Kjersem, J.B.; Ikdahl, T.; Lingjaerde, O.C.; Guren, T.; Tveit, K.M.; Kure, E.H. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol. Oncol., 2014, 8(1), 59-67.
[http://dx.doi.org/10.1016/j.molonc.2013.09.001] [PMID: 24119443]
[81]
Ulivi, P.; Canale, M.; Passardi, A.; Marisi, G.; Valgiusti, M.; Frassineti, G.L.; Calistri, D.; Amadori, D.; Scarpi, E. Circulating plasma levels of miR-20b, miR-29b and miR-155 as predictors of bevacizumab efficacy in patients with metastatic colorectal cancer. Int. J. Mol. Sci., 2018, 19(1), E307.
[http://dx.doi.org/10.3390/ijms19010307] [PMID: 29361687]
[82]
Xia, Z.S.; Wang, L.; Yu, T.; Zhong, W.; Lian, G.D.; Wu, D.; Zhou, H.M.; Chen, G.C. MiR-5000-3p, miR-5009-3P and miR-552: Potential microRNA biomarkers of side population cells in colon cancer. Oncol. Rep., 2014, 32(2), 589-596.
[http://dx.doi.org/10.3892/or.2014.3232] [PMID: 24898979]
[83]
Hu, J.; Xu, Y.; Cai, S. Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma. Eur. J. Med. Res., 2015, 20, 95.
[http://dx.doi.org/10.1186/s40001-015-0183-8] [PMID: 26626874]
[84]
Zhu, Y.; Peng, Q.; Lin, Y.; Zou, L.; Shen, P.; Chen, F.; Min, M.; Shen, L.; Chen, J.; Shen, B. Identification of biomarker microRNAs for predicting the response of colorectal cancer to neoadjuvant chemoradiotherapy based on microRNA regulatory network. Oncotarget, 2017, 8(2), 2233-2248.
[http://dx.doi.org/10.18632/oncotarget.13659] [PMID: 27903980]
[85]
Khoshinani, H.M.; Afshar, S.; Pashaki, A.S.; Mahdavinezhad, A.; Nikzad, S.; Najafi, R.; Amini, R.; Gholami, M.H.; Khoshghadam, A.; Saidijam, M. Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line. Jpn. J. Radiol., 2017, 35(11), 664-672.
[http://dx.doi.org/10.1007/s11604-017-0679-y] [PMID: 28879560]
[86]
Yang, X.D.; Xu, X.H.; Zhang, S.Y.; Wu, Y.; Xing, C.G.; Ru, G.; Xu, H.T.; Cao, J.P. Role of miR-100 in the radioresistance of colorectal cancer cells. Am. J. Cancer Res., 2015, 5(2), 545-559.
[PMID: 25973296]
[87]
Ma, W.; Yu, J.; Qi, X.; Liang, L.; Zhang, Y.; Ding, Y.; Lin, X.; Li, G.; Ding, Y. Radiation-induced microRNA-622 causes radioresistance in colorectal cancer cells by down-regulating Rb. Oncotarget, 2015, 6(18), 15984-15994.
[http://dx.doi.org/10.18632/oncotarget.3762] [PMID: 25961730]
[88]
Svoboda, M.; Izakovicova Holla, L.; Sefr, R.; Vrtkova, I.; Kocakova, I.; Tichy, B.; Dvorak, J. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int. J. Oncol., 2008, 33(3), 541-547.
[PMID: 18695884]
[89]
Campayo, M.; Navarro, A.; Benítez, J.C.; Santasusagna, S.; Ferrer, C.; Monzó, M.; Cirera, L. miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer. PLoS One, 2018, 13(11), e0206542.
[http://dx.doi.org/10.1371/journal.pone.0206542] [PMID: 30388154]
[90]
Du, B.; Wang, T.; Yang, X.; Wang, J.; Shi, X.; Wang, X.; Wu, D.; Feng, L.; Chen, L.; Zhang, W. SOX9, miR-495, miR-590-3p, and miR-320d were identified as chemoradiotherapy-sensitive genes and miRNAs in colorectal cancer patients based on a microarray dataset. Neoplasma, 2019, 66(1), 8-19.
[http://dx.doi.org/10.4149/neo_2018_170324N214] [PMID: 30509082]
[91]
Kong, J.C.; Guerra, G.R.; Warrier, S.K.; Lynch, A.C.; Michael, M.; Ngan, S.Y.; Phillips, W.; Ramsay, G.; Heriot, A.G. Prognostic value of tumour regression grade in locally advanced rectal cancer: A systematic review and meta-analysis. Colorectal Dis., 2018, 20(7), 574-585.
[http://dx.doi.org/10.1111/codi.14106] [PMID: 29582537]
[92]
Kheirelseid, E.A.; Miller, N.; Chang, K.H.; Curran, C.; Hennessey, E.; Sheehan, M.; Newell, J.; Lemetre, C.; Balls, G.; Kerin, M.J. miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int. J. Colorectal Dis., 2013, 28(2), 247-260.
[http://dx.doi.org/10.1007/s00384-012-1549-9] [PMID: 22903298]
[93]
Du, B.; Wang, X.; Wu, D.; Wang, T.; Yang, X.; Wang, J.; Shi, X.; Chen, L.; Zhang, W. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer. Mol. Med. Rep., 2018, 18(2), 1909-1916.
[http://dx.doi.org/10.3892/mmr.2018.9215] [PMID: 29956755]
[94]
Svoboda, M.; Sana, J.; Fabian, P.; Kocakova, I.; Gombosova, J.; Nekvindova, J.; Radova, L.; Vyzula, R.; Slaby, O. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat. Oncol., 2012, 7, 195.
[http://dx.doi.org/10.1186/1748-717X-7-195] [PMID: 23167930]
[95]
Cunningham, D.; Atkin, W.; Lenz, H.J.; Lynch, H.T.; Minsky, B.; Nordlinger, B.; Starling, N. Colorectal cancer. Lancet, 2010, 375(9719), 1030-1047.
[http://dx.doi.org/10.1016/S0140-6736(10)60353-4] [PMID: 20304247]
[96]
Price, T.J.; Peeters, M.; Kim, T.W.; Li, J.; Cascinu, S.; Ruff, P.; Suresh, A.S.; Thomas, A.; Tjulandin, S.; Zhang, K.; Murugappan, S.; Sidhu, R. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non inferiority phase 3 study. Lancet Oncol., 2014, 15(6), 569-579.
[http://dx.doi.org/10.1016/S1470-2045(14)70118-4] [PMID: 24739896]
[97]
Van Cutsem, E.; Köhne, C.H.; Láng, I.; Folprecht, G.; Nowacki, M.P.; Cascinu, S.; Shchepotin, I.; Maurel, J.; Cunningham, D.; Tejpar, S.; Schlichting, M.; Zubel, A.; Celik, I.; Rougier, P.; Ciardiello, F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol., 2011, 29(15), 2011-2019.
[http://dx.doi.org/10.1200/JCO.2010.33.5091] [PMID: 21502544]
[98]
Liu, R.; Lu, Z.; Gu, J.; Liu, J.; Huang, E.; Liu, X.; Wang, L.; Yang, J.; Deng, Y.; Qian, J.; Luo, F.; Wang, Z.; Zhang, H.; Jiang, X.; Zhang, D.; Qian, J.; Liu, G.; Zhu, H.; Qian, Y.; Liu, Z.; Chu, Y. MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. Gastroenterology, 2018, 154(3), 637-651.e7.
[99]
Colangelo, T.; Polcaro, G.; Ziccardi, P.; Muccillo, L.; Galgani, M.; Pucci, B.; Milone, M.R.; Budillon, A.; Santopaolo, M.; Mazzoccoli, G.; Matarese, G.; Sabatino, L.; Colantuoni, V. The miR-27acalreticulin axis affects drug-induced immunogenic cell death in human colorectal cancer cells. Cell Death Dis., 2016, 7e2108,
[http://dx.doi.org/10.1038/cddis.2016.29] [PMID: 26913599]
[100]
Zhu, J.; Chen, L.; Zou, L.; Yang, P.; Wu, R.; Mao, Y.; Zhou, H.; Li, R.; Wang, K.; Wang, W.; Hua, D.; Zhang, X. MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum. Immunol., 2014, 75(4), 348-353.
[http://dx.doi.org/10.1016/j.humimm.2014.01.006] [PMID: 24468585]
[101]
Dou, R.; Nishihara, R.; Cao, Y.; Hamada, T.; Mima, K.; Masuda, A.; Masugi, Y.; Shi, Y.; Gu, M.; Li, W.; da Silva, A.; Nosho, K.; Zhang, X.; Meyerhardt, J.A.; Giovannucci, E.L.; Chan, A.T.; Fuchs, C.S.; Qian, Z.R.; Ogino, S. MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol. Res., 2016, 4(11), 927-935.
[http://dx.doi.org/10.1158/2326-6066.CIR-16-0112] [PMID: 27737877]
[102]
Mima, K.; Nishihara, R.; Nowak, J.A.; Kim, S.A.; Song, M.; Inamura, K.; Sukawa, Y.; Masuda, A.; Yang, J.; Dou, R.; Nosho, K.; Baba, H.; Giovannucci, E.L.; Bowden, M.; Loda, M.; Giannakis, M.; Bass, A.J.; Dranoff, G.; Freeman, G.J.; Chan, A.T.; Fuchs, C.S.; Qian, Z.R.; Ogino, S. MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol. Res., 2016, 4(1), 33-40.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0084] [PMID: 26419959]
[103]
Li, X.; Nie, J.; Mei, Q.; Han, W.D. MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma. World J. Gastroenterol., 2016, 22(23), 5317-5331.
[http://dx.doi.org/10.3748/wjg.v22.i23.5317] [PMID: 27340348]
[104]
Wang, W.T.; Chen, Y.Q. Circulating miRNAs in cancer: from detection to therapy. J. Hematol. Oncol., 2014, 7, 86.
[http://dx.doi.org/10.1186/s13045-014-0086-0] [PMID: 25476853]

Rights & Permissions Print Cite
Article Metrics
35
7
© 2024 Bentham Science Publishers | Privacy Policy